PRESENTATION

Q3 2025 — Presentation

Q3 2025PDF · 34 pages2.3 MB
Third-Quarter 2025
Sales and Earnings
Merck & Co., Inc., Rahway, N.J., USA
October 30, 2025

-- 1 of 34 --

Agenda
2
Strategy and Business Update
Robert M. Davis
Chairman and Chief Executive Officer
Agenda
Financial Results and Outlook
Caroline Litchfield
Executive Vice President and Chief Financial Officer
Research Update
Dr. Dean Y. Li
Executive Vice President and President, Research Laboratories
Question & Answer Session

-- 2 of 34 --

Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA
3
This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the
safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and
expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to
pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If
underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the
forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including
interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost containment; technological advances, new products and patents
attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to
accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign
risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation,
including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future
events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements
can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

-- 3 of 34 --

Strategy and
Business Update
Robert M. Davis
Chairman and Chief Executive Officer
4

-- 4 of 34 --

55
Delivering value to patients and customers through innovative portfolio of
medicines and vaccines
Advancing strongest and deepest pipeline in recent memory
with ~80 Phase 3 trials underway
Fueling portfolio transformation and growth with investment
in over 20 current and future launch opportunities
Executing science- and value-driven business development
1. Does not include any future business development transactions in R&D
>$70 billion
investment in U.S.
manufacturing and R&D 1
beginning in 2025

-- 5 of 34 --

¹Weber Shandwick/KCR Research, 2020 / AMO 2019 	6
Q3 Worldwide Sales
$17.3B
Strength in Oncology and Animal Health with
increasing contributions from new launches
+4% nominal
+3% ex-FX

-- 6 of 34 --

Driving value by progressing innovative pipeline
7
Received FDA approval of KEYTRUDA QLEX and CHMP
positive opinion 1
Presented data at ESMO for novel pipeline candidates
and broad oncology portfolio
Announced positive topline results for WELIREG in
LITESPARK-011 and LITESPARK-022
Oncology
Announced positive topline results for enlicitide in
Phase 3 CORALreef Lipids study
Presented full results for WINREVAIR in recently
diagnosed adults with PAH in HYPERION study
Received FDA approval for updated indication for
WINREVAIR based on ZENITH
Cardiopulmonary
Presented Phase 3 data for doravirine + islatravir for
HIV-1 treatment in adults with suppressed virus
Presented additional Phase 3 data for CAPVAXIVE at
ESCMIDInfectious
Disease
Accelerated Phase 3 development for MK-3000
Presented first-time Phase 1 data for MK-8748 in
NVAMD and RVO
Ophthalmology
Expanded tulisokibart development program in
immunology in three new disease areas
Immunology
1. MK-3475A to be marketed in the EU as KEYTRUDA SC

-- 7 of 34 --

88
Completed strategic acquisition of Verona Pharma in October
First novel inhaled maintenance treatment for adults
with COPD in more than 20 years
Multibillion dollar commercial opportunity with potential
to positively impact patients and drive both near- and
long-term revenue growth

-- 8 of 34 --

9
Well positioned to drive next chapter of
success
Executing Business Development
Actively pursuing additional science-driven
value-creating transactions
Launching New Growth Drivers
>$50B commercial opportunity by mid-2030s from
recent launches and late-phase pipeline
Advancing Early- and Late-Phase Pipeline
Tripled late-phase pipeline since 2021
Delivering the next
wave of innovation to
transform our portfolio

-- 9 of 34 --

Financial Results
and Outlook
Caroline Litchfield
Executive Vice President and
Chief Financial Officer
10

-- 10 of 34 --

Q3 performance driven by demand for our innovative portfolio
11
1. Worldwide Sales includes Other Revenue 2. There were no sales of GARDASIL in China in 3Q25. Sales of GARDASIL in China were $0.5 billion in 3Q24
Human Health
$15.6B+4% nominal
+3% ex-FX
+8% ex-GARDASIL China2 nominal,
+7% ex-FX
$17.3B+4% nominal
+3% ex-FX
+7% ex-GARDASIL China 2 , nominal & ex-FX
WORLDWIDE SALES1 Animal Health
$1.6B+9% nominal
+7% ex-FX

-- 11 of 34 --

Oncology: KEYTRUDA continues to benefit patients and drive growth
12
KEYTRUDA sales of $8.1B increased 8%,
driven by strong demand from metastatic
indications and robust uptake in earlier-stage
cancers
‒ 	Growth driven by usage in tumors
predominantly affecting women, including those
with certain cervical, breast, and endometrial
cancers
‒ 	Increased use of KEYTRUDA in combination with
enfortumab vedotin in first-line, locally advanced
or metastatic urothelial cancer
‒ 	In the U.S., growth benefitted by ~$100M due to
an extra Tuesday of shipments partially offset by
other channel movements
3Q23 	3Q24 	3Q25
$6.3B
+17%
$8.1B
+8%$7.4B
+21%1
Growth rates exclude the impact of foreign exchange
1. ~3 percentage points of negative impact of foreign exchange was due to devaluation of Argentine peso, which was largely offset by inflation-related price increases, consistent with practice in that market

-- 12 of 34 --

Oncology: Continued growth across broad portfolio
13
WELIREG sales grew 41%, driven by demand
in the U.S. and continued launch uptake in
certain European markets
Lynparza 1 sales grew 12%, primarily due to
higher demand in the U.S. and certain
international markets
Lenvima 2 sales grew 2%, primarily due to
higher sales in the U.S. reflecting higher
demand, partially offset by lower pricing
Growth rates exclude the impact of foreign exchange
1. In collaboration with AstraZeneca 2. In collaboration with Eisai
3Q23 	3Q24 	3Q25
$337M
+13%
$299M
+6%
$379M
+12%
3Q23 	3Q24 	3Q25
$251M
-4%
$260M
+30%
$258M
+2%
3Q23 	3Q24 	3Q25
$139M
+157%
$54M
+43%
$196M
+41%

-- 13 of 34 --

Vaccines: GARDASIL protecting lives from HPV-related cancers
14
GARDASIL sales of $1.7B decreased 25%, driven
primarily by China
‒ 	Excluding China, decline of 3% driven by lower sales
in Japan following expiration of reimbursement for
catch-up cohort, partially offset by growth of 13%
in the U.S. driven by price and CDC purchasing
patterns
3Q23 	3Q24 	3Q25
$2.3B
-10%
$1.7B
-25%
$2.6B
+16%
Growth rates exclude the impact of foreign exchange

-- 14 of 34 --

Vaccines & Infectious Disease: Broad portfolio driving impact for patients
15
CAPVAXIVE 1 sales of $244M driven by demand
from retail pharmacies and non-retail customers,
as well as expected seasonal inventory build
VAXNEUVANCE sales of $226M decreased 7%
‒ 	In the U.S., competitive pressure offset favorable
CDC stockpile activity
‒ 	Outside the U.S., competitor preferential
recommendation in Japan more than offset growth
in certain international markets
ENFLONSIA sales of $79M reflect initial stocking
in the U.S.
3Q23 	3Q24 	3Q25
$1.7B
+40%
3Q23 	3Q24 	3Q25
$244M
$214M $239M
+13% $226M
-7%
Growth rates exclude the impact of foreign exchange
1. Launched in 3Q24
$47M

-- 15 of 34 --

3Q23 	3Q24 	3Q25
$2.3B
-10%
WINREVAIR: Continuing to benefit more patients with PAH
16
In the U.S., continued growth in new patient starts
and total prescriptions, partially offset by timing of
distributor purchases
‒ 	~1,500 new patients prescribed
‒ 	>24,000 total prescriptions dispensed
‒ 	>9,700 total patients prescribed since launch 1
‒ 	>7,800 patients with claims approved by payers started
treatment since launch
‒ 	>83,000 total prescriptions filled since launch
Strong breadth and depth of prescribers
‒ 	>1,400 physicians have written at least one prescription since
launch
‒ 	Increased prescriptions for patients whose background PAH
therapies do not include a prostacyclin
Ex-U.S., making progress with approvals and
reimbursement
Growth rates exclude the impact of foreign exchange
1. Launched in 2Q24
$149M
$360M
+141%

-- 16 of 34 --

Animal Health: Strong growth driven by livestock portfolio
17
Animal Health sales increased 7% to $1.6B
‒ 	Livestock sales grew 14%, driven by higher
demand across all species and timing of sales
‒ 	Companion Animal sales declined 3% due to
reduction in veterinary visits and competition in
parasiticides, partially offset by price, improved
supply, and new product launches
Growth rates exclude the impact of foreign exchange
1. ~2 percentage points of negative impact of foreign exchange due to devaluation of Argentine peso, which was largely offset by inflation-related price increases, consistent with practice in that market
3Q23 	3Q24 	3Q25
$1.4B
+2%
$1.5B
+11%1
$1.6B
+7%

-- 17 of 34 --

Q3 2025 non-GAAP financial results summary 1
$ in billions, except EPS amounts
18
1. The company is providing certain 2025 and 2024 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business
performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess
performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, annual employee
compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. This information should be considered in addition to, but not as a substitute for or
superior to, information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to the earnings release. 2. Q3 2025 GAAP EPS of $2.32 3. Q3 2025
includes a charge of $0.10 related to the LaNova technology transfer milestone payment. Q3 2024 includes a net charge of $0.79 for the EyeBio (including milestone), Curon, and Daiichi Sankyo transactions.
Q3 2025 	Q3 2024 	Change Change
Ex-FX
Sales 	$17.3 	$16.7 	+4% 	+3%
Non-GAAP Gross Margin 	81.9% 	80.5% 	+1.4 pts 	+1.6 pts
Non-GAAP Operating
Expenses $6.6 	$8.5 	-22% 	-23%
Non-GAAP Tax Rate 	13.4% 	21.9% 	-8.5 pts 	N/A
Non-GAAP EPS2,3 $2.58 	$1.57 	+64% 	+65%

-- 18 of 34 --

Updated 2025 financial outlook
19
1. Guidance does not assume any additional significant potential business development transactions
Prior Guidance 	Updated Guidance 	Key Assumptions
Revenue 	$64.3B to $65.3B 	$64.5B to $65.0B • 	Continues to assume ~0.5 percentage point FX headwind
• 	Implies +1% nominal (+1% to +2% ex-FX)
Non-GAAP
Gross Margin Rate ~82.0% 	~82.0% • 	Includes updated estimate of <$100M of costs related to
tariffs
Non-GAAP
Operating Expenses1 	$25.6B to $26.4B 	$25.9B to $26.4B
Other (Income) / Expense 	~$300M to ~$400M of expense 	~$400M to ~$500M of expense • 	Now includes financing costs related to the acquisition of
Verona Pharma
Tax Rate 	~15.0% to 16.0% 	~14.0% to 15.0% 	• 	Now includes benefit from certain discrete items
Shares Outstanding 	~2.51B 	~2.51B
Non-GAAP EPS1 	$8.87 to $8.97 	$8.93 to $8.98
• 	Continues to assume ~$0.15 FX headwind
• 	Now includes net $0.05 benefit related to the restructured
agreement for Koselugo and an estimated negative impact
related to the acquisition of Verona

-- 19 of 34 --

Key modeling considerations
20
KEYTRUDA YoY growth in 4Q expected to be negatively impacted by ~$200M due to timing of U.S.
wholesaler purchases in 4Q 2024
ENFLONSIA 	Initial sales in 3Q reflect stocking ahead of expected use in this RSV season
Operating
Expenses
Expect acceleration in underlying operating expense growth in 2026 driven by investment
in both R&D and SG&A to fuel pipeline and new launches

-- 20 of 34 --

Remain committed to balanced capital allocation strategy
Q3 Spend ($ in billions) 1
21
Continue to invest in our
pipeline and business, as well
as augment our pipeline with
value-enhancing business
development, while returning
cash to shareholders
1. Reflects quarter spend
2. Reflects R&D excluding Business Development
Capital allocation order of priority
2
$3.2
$1.0
$2.0
$0.4
$1.3
After-Tax R&D 	CapEx 	Dividends
Paid
Business
Development
(ex-divestitures)
Share Repurchase

-- 21 of 34 --

Research Update
Dr. Dean Y. Li
Executive Vice President and President,
Research Laboratories
22

-- 22 of 34 --

KEYTRUDA continues to expand benefits, including for earlier-stage
patients
23
‒ 	Received FDA approval for subcutaneous pembrolizumab1
across all solid tumor indications approved for IV KEYTRUDA
‒ 	Subcutaneous administration in as little as one minute2
‒ 	Potential to provide flexibility in site of care while helping to
increase efficiency in and access to health care systems
‒ 	Opportunity for use in certain patients with earlier-stage
disease
‒ 	Granted positive CHMP opinion in the EU
‒ 	KEYNOTE-689: Received EC approval for KEYTRUDA in perioperative treatment of certain patients whose
tumors express PD-L1 CPS ≥1 with resectable, locally advanced HNSCC
‒ 	10 earlier-stage approvals to date
KEYTRUDA QLEX
KEYTRUDA
1. Pembrolizumab with berahyaluronidase alfa 2. When administered every 3 weeks

-- 23 of 34 --

Continued momentum across diversified oncology portfolio in multiple
tumor types
24
KEYTRUDA
Data presented at ESMO in two
Presidential Symposium sessions for:
• 	KEYNOTE-B96: PFS and OS data in
patients whose tumors express PD-L1,
treated with KEYTRUDA + chemo
(PDUFA February 20 th)
• 	KEYNOTE-9051 : EFS and OS data in
cisplatin-ineligible patients with MIBC
treated with perioperative KEYTRUDA
+ enfortumab vedotin (PDUFA April 7 th)
‒ 	5th earlier stage trial to demonstrate OS
As well as long-term follow-up data:
• 	Eight- and ten-year exploratory
results from multiple monotherapy
trials in advanced or metastatic NSCLC
• 	Five-year exploratory follow-up in
earlier-stage NSCLC setting
Antibody Drug Conjugates
Data presented at ESMO for
investigational ADCs including:
Sacituzumab tirumotecan (TROP2)2
• 	Results from the Phase 3 China-only
OptiTROP-Lung043 study in EGFRm
NSCLC and OptiTROP-Breast023 study
in locally advanced/metastatic
HR+/HER2- breast cancer
• 	Earlier-phase data3 in other tumor
types including advanced cervical and
mCRPC
Raludotatug deruxtecan4 (CDH6)
• 	Results from the Phase 2/3 REJOICE-
Ovarian01 study in previously treated
platinum-resistant ovarian, primary
peritoneal or fallopian tube cancer
Ifinatamab deruxtecan4 (B7H3)
• 	Results from the Phase 2 IDeate-Lung-
01 study in eSCLC
WELIREG
Positive topline results announced from:
• 	LITESPARK-011 in advanced RCC
‒ 	First pivotal study of WELIREG
combination regimen and third pivotal
study of Lenvima 5 as part of combination
regimen
• 	LITESPARK-022 in adjuvant RCC
‒ 	Second positive Phase 3 for WELIREG as
part of combination regimen
1. In collaboration with Pfizer and Astellas 2. In collaboration with Kelun 3. Conducted by Kelun 4. In collaboration with Daiichi Sankyo 5. In collaboration with Eisai

-- 24 of 34 --

Clinical progress across vaccines and infectious diseases
25
CAPVAXIVE
• 	Received MHLW approval in
Japan for prevention of
pneumococcal infections in elderly
and adults at high risk
• 	Presented STRIDE-13 Phase 3
results in children and
adolescents aged 2 to <18 who are
at increased risk for
pneumococcal disease at ESCMID
(PDUFA June 18th)
ENFLONSIA
• 	Now available for infants born in or
entering first RSV season
• 	Received positive CHMP opinion
from EMA
HIV
• 	Presented 48-week Phase 3
results for DOR/ISL as once-daily,
oral 2-drug regimen for adults
with virologically suppressed HIV-1
infection
• 	Presented 96-week Phase 2
outcomes data for ISL/LEN1 as
once-weekly oral regimen for
adults with virologically
suppressed HIV-1 infection
1. In collaboration with Gilead

-- 25 of 34 --

Expanding and advancing late-stage programs in immunology and
ophthalmology
26
Immunology 	Indication 	Trial 	Phase 1 	Phase 2 	Phase 3
Tulisokibart
TL1A
UC 	ATLAS-UC
CD 	ARES-CD
SSc-ILD 	ATHENA-SSc-ILD
HS 	MK-7240-012
r-axSpA 	MK-7240-014
RA 	MK-7240-013
Reflects an update this quarter
Ophthalmology 	Indication 	Trial 	Phase 1 	Phase 2 	Phase 3
MK-3000
Wnt
DME 	BRUNELLO
DME 	BAROLO
NVAMD, RVO 	SUPER TUSCAN
NVAMD, RVO 	RIOJA
Now enrolling
MK-8748
Tie2/VEGF
Now enrolling
Now enrolling
Now enrolling
Phase 1 data presented at Eyecelerator at AAO 2025
Initiating late-stage studies in 2026
Enrollment Complete
Enrollment Complete
UC = Ulcerative colitis; CD = Crohn’s disease; SSc-ILD = Systemic sclerosis associated with interstitial lung disease; HS = Hidradenitis suppurativa; r-axSpA = Radiographic axial spondyloarthritis;
RA = Rheumatoid arthritis; DME = Diabetic macular edema; NVAMD = Neovascular age-related macular degeneration; RVO = Retinal vein occlusion

-- 26 of 34 --

Committed to alleviating burden of cardiopulmonary diseases
27
• 	HYPERION: Phase 3 data in
recently diagnosed adults with
PAH on background therapy
presented at ERS and published in
NEJM
• 	ZENITH: Received FDA approval
for updated product label1
• 	First PAH drug indicated for
reductions in death and lung
transplantation1
First and only activin signaling inhibitor
• 	Advancing ongoing work in non-
cystic fibrosis bronchiectasis
• 	Evaluating utility in additional
indications, combinations, and
formulations
First-in-class selective dual inhibitor of
PDE3 and PDE4
• 	CORALreef Lipids: Met all primary
and key secondary endpoints in
third positive Phase 3 study
• 	Highlighting cardiopulmonary
program at AHA Investor Event on
Sunday, November 9 th
Enlicitide a potential first-of-its-kind
oral PCSK9 inhibitor
1. WINREVAIR is now FDA-approved on top of background therapy in adults with PAH, WHO FC III or IV, at high risk of mortality to improve exercise capacity and WHO functional class, and reduce the risk
of clinical worsening events, including hospitalization for PAH, lung transplantation and death. Expanded indication includes components of the clinical worsening events: hospitalization for PAH, lung
transplantation and death.

-- 27 of 34 --

Many important upcoming milestones through 1H 2026
28
Oncology
KEYTRUDA
• 	KEYNOTE-B96 PDUFA date February 20th
• 	KEYNOTE-905 1 PDUFA date April 7 th
Infectious Disease
Doravirine/Islatravir
• 	PDUFA date April 28th
Islatravir/Lenacapavir2
• 	PCD in April for Phase 3 ISLEND-1 and ISLEND-2
trials in HIV treatment
CAPVAXIVE
• 	STRIDE-13 label expansion PDUFA date June 18th
Immunology
Tulisokibart
• 	PCD in May for Phase 2 ATHENA trial in SSc-ILD
Cardiopulmonary
WINREVAIR
• 	Presentation of detailed findings from Phase 2
CADENCE trial in Cpc-PH due to HFpEF
Enlicitide decanoate
• 	Presentation of detailed findings from first 3 trials
of CORALreef Phase 3 program
1. In collaboration with Pfizer and Astellas 2. In collaboration with Gilead

-- 28 of 34 --

Q&A
Robert M. Davis
Chairman and Chief Executive Officer
Dr. Dean Y. Li
Executive Vice President and President, Research Laboratories
Caroline Litchfield
Executive Vice President and Chief Financial Officer
Peter Dannenbaum
Senior Vice President, Investor Relations

-- 29 of 34 --

30
Appendix

-- 30 of 34 --

Q3 2025 GAAP financial results summary
$ in billions, EPS amounts
31
1. Q3 2025 GAAP results include $300 million charge related to the LaNova technology transfer milestone payment. 3Q24 GAAP results include $2.2 billion charge related to the acquisitions of EyeBio and
MK-1045. 2. Q3 2025 GAAP results include charge of $0.10 per share related to the LaNova technology transfer milestone payment. 3Q24 GAAP results include net charge of $0.79 per share for the EyeBio
(including milestone), Curon and Daiichi Sankyo transactions.
Q3 2025 	Q3 2024 	Change 	Change Ex-FX
Sales 	$17.3 	$16.7 	+4% 	+3%
Operating Expenses
(SG&A and R&D)1 $6.9 	$8.6 	-20% 	-21%
Tax Rate 	14.2% 	22.7% 	-8.5 pts 	N/A
GAAP EPS2 $2.32 	$1.24 	+87% 	+88%

-- 31 of 34 --

$12.7
$4.0
$8.1
$2.4 $4.3
$0
$3
$6
$9
$12
$15
After-Tax R&D 	CapEx 	Dividends Paid 	Business
Development
(ex-divestitures)
Share
Repurchase
~$21B
Over 5 years, including expanding
manufacturing capacity for Oncology, Vaccines,
and Animal Health. Includes >$11B in the U.S.
Billions
Commitment to the dividend
Capital allocation: Trailing twelve months
32
Well-positioned balance sheet with
capacity to fund additional
investments in R&D and
manufacturing as well as value-
enhancing business development
opportunities
Capital allocation order of priority
1. Reflects R&D excluding Business Development
2. Includes BD payments reflected in operating cash flow
E
Capital investments
2025 to 2029
Over the past 12 months
2
1
$1.84 	$1.88 	$1.92
$2.20 $2.44 $2.60 $2.76 $2.92 	$3.08 $3.24
2016 	2017 	2018 	2019 	2020 	2021 	2022 	2023 	2024 	2025
Dollars per share
+2% 	+2% 	+2%
+11%
+15%
+7% +6% +6% 	+5% +5%
Executing upon balanced capital allocation strategy

-- 32 of 34 --

Driving value for patients and shareholders by progressing our pipeline
33
Notable regulatory milestones since the last earnings call:
In the U.S., the FDA:
• 	Approved updated indication for WINREVAIR in adults with PAH, WHO Group 1 PH based
on ZENITH
• 	Accepted for priority review new sBLAs for KEYTRUDA and KEYTRUDA QLEX in
combination with enfortumab vedotin as perioperative treatment for certain patients with
MIBC based on KEYNOTE-905 1
• 	Accepted for priority review a new sBLA for KEYTRUDA plus chemotherapy with or
without bevacizumab for certain patients with platinum-resistant recurrent ovarian cancer
based on KEYNOTE-B96
• 	Approved KEYTRUDA QLEX injection for subcutaneous administration in adults across all
solid tumor indications for KEYTRUDA
• 	Granted I-DXd Breakthrough Therapy Designation for patients with pretreated ES-SCLC
• 	Granted R-DXd Breakthrough Therapy Designation for patients with CDH6 expressing
platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers previously
treated with bevacizumab
In the EU:
• 	EC approved KEYTRUDA as part of a perioperative regimen in locally advanced HNSCC
based on the Phase 3 KEYNOTE-689 trial
• 	CHMP adopted a positive opinion for ENFLONSIA for the prevention of RSV in infants
during their first RSV season based on the Phase2b/3 CLEVER and Phase 3 SMART trials
• 	CHMP adopted a positive opinion for subcutaneous administration of KEYTRUDA for all
adult indications approved in the EU for KEYTRUDA based on the pivotal MK-3475A-D77
trial
In Japan, the MHLW:
• 	Approved GARDASIL9 for males 9 years and older for the prevention of anal cancer,
precursor lesions, and genital warts
• 	Approved CAPVAXIVE for the prevention of invasive pneumococcal disease and
pneumococcal pneumonia in adults 65 years and older at increased risk based on the
STRIDE-9 trial and in adults 18 at increased risk for diseases based on the STRIDE-8 trial
Notable data & clinical advancements since the last earnings call:
Presented data for:
• 	Phase 3 STRIDE-13 trial evaluating CAPVAXIVE at the European Society of Clinical
Microbiology and Infectious Diseases Conference on Vaccines demonstrating positive
immune responses in children and adolescents at increased risk of pneumococcal
disease
• 	Phase 2 IDeate-Lung01 trial evaluating I-DXd at the World Conference on Lung Cancer
demonstrating clinically meaningful response rates in patients with previously treated
ES-SCLC
• 	Phase 3 HYPERION trial evaluating WINREVAIR at the European Respiratory Society
Congress demonstrating reduced risk of clinical worsening events in adults recently
diagnosed with PAH WHO FC II or III at intermediate or high risk of disease
progression.
• 	Broad oncology portfolio at the European Society for Medical Oncology, including for
KEYTRUDA, KEYTRUDA QLEX, WELIREG, R-DXd, I-DXd, and sac-TMT, including
positive results from KEYNOTE-9051 and KEYNOTE-B96
• 	HIV treatment and prevention pipeline at the European AIDS Conference, including for
doravirine/islatravir, islatravir/lenacapavir2, and MK-8527
Announced:
• 	Positive topline results from the Phase 3 LITESPARK-011 evaluating WELIREG in
combination with Lenvima3 in certain previously treated patients with advanced RCC
• 	Positive topline results from the Phase 3 LITESPSARK-022 trials evaluating WELIREG
in combination with KEYTRUDA in certain patients with ccRCC following nephrectomy
• 	Positive topline results from the Phase 3 CORALreef Lipids trial evaluating enlicitide
for the treatment of adults with hypercholesterolemia on a moderate or high intensity
statin or with documented statin intolerance
1. In collaboration with Pfizer and Astellas 2. In collaboration with Gilead 3. In collaboration with Eisai

-- 33 of 34 --

MK-8527
HIV-1 PrEP
MK-8591A (doravirine + islatravir)
HIV-1 Infection (EU)
MK-8591D (islatravir + lenacapavir) 1,4
HIV-1 Infection
LAGEVRIO (MK-4482) 1,5
COVID-19 Antiviral (U.S.)
Broad and innovative pipeline to address significant unmet medical needs
34
As of October 30, 2025
Phase 3
Oncology
MK-1022 (patritumab deruxtecan) 1
Breast
MK-1026 (nemtabrutinib)
Hematological Malignancies
MK-1084 2
CRC
NSCLC
MK-1308A (quavonlimab +
pembrolizumab)
RCC
MK-2140 (zilovertamab vedotin)
Hematological Malignancies
MK-2400 (ifinatamab deruxtecan) 1
Esophageal
Prostate
SCLC
MK-2870 (sacituzumab tirumotecan) 1,3
Breast
Cervical
Endometrial
Gastric
NSCLC
Ovarian
KEYTRUDA (MK-3475)
HCC (EU)
SCLC
MK-3543 (bomedemstat)
Myeloproliferative Disorders
MK-5684 (opevesostat)
Prostate
LYNPARZA (MK-7339) 1,2
NSCLC
SCLC
V940 (intismeran autogene) 1,2
Melanoma
NSCLC
Infectious Disease
MK-7240 (tulisokibart)
Crohn’s Disease
Ulcerative Colitis
Immunology
Cardiopulmonary
MK-0616 (enlicitide decanoate)
Hypercholesterolemia
MK-30006
Diabetic Macular Edema
Ophthalmology
Phase 2
KEYTRUDA (MK-3475)
Prostate
KEYTRUDA QLEX (MK-3475A) 7
Hematological Malignancies (U.S.)
MK-5684 (opevesostat)
Breast
Endometrial
Ovarian
MK-5909 (raludotatug
deruxtecan) 1
Biliary
Bladder
Cervical
CRC
Endometrial
Gastric
NSCLC
Ovarian
Pancreas
RCC
SCLC
MK-6070 (gocatamig)
SCLC
WELIREG (MK-6482)
Breast
V940 (intismeran autogene) 1,2
Bladder
RCC
MK-1022 (patritumab
deruxtecan) 1,3
Biliary
Bladder
Cervical
CRC
Endometrial
Esophageal
Gastric
HCC
HNSCC
Melanoma
NSCLC
Ovarian
Pancreas
Prostate
MK-2400 (ifinatamab deruxtecan) 1
Biliary
Bladder
Breast
Cervical
CRC
Endometrial
HCC
HNSCC
Melanoma
NSCLC
Ovarian
Pancreas
MK-2870 (sacituzumab
tirumotecan) 1,3
Biliary
Bladder
CRC
Esophageal
Neoplasm Malignant
Pancreatic
Oncology
Infectious Disease
MK-8591B (islatravir+ulonivirine)
HIV-1 Infection
MK-5475
PH-COPD
ensifentrine + glycopyrrolate (MK-
5884A)
COPD
MK-6024 (efinopegdutide)
MASH
MK-7262
Atherosclerosis
WINREVAIR (MK-7962)
Pulmonary Hypertension due to
Left Heart Disease
Cardiopulmonary
MK-7240 (tulisokibart)
Axial Spondyloarthritis
Hidradenitis Suppurativa
Rheumatoid Arthritis
Systemic Sclerosis
Immunology
MK-1167
Alzheimer’s Disease
MK-2214
Alzheimer’s Disease
Neuroscience
Under regulatory review
Oncology
KEYTRUDA (MK-3475)
HNSCC (JPN)
MIBC (U.S.)
Ovarian (U.S., EU)
KEYTRUDA QLEX (MK-3475A)
MIBC (U.S.)
Previously Approved Tumors (EU) 7
Infectious Disease
ENFLONSIA (MK-1654)
Respiratory Syncytial Virus (EU, JPN)
MK-8591A (doravirine + islatravir)
HIV-1 Infection (U.S., JPN)
1. Being developed in a collaboration 2. Being developed in combination with KEYTRUDA 3. Being developed as monotherapy and/or in combination with KEYTRUDA 4. On partial clinical hold for higher doses of islatravir than those used in current clinical trials
5. Available in the U.S. under Emergency Use Authorization 6. Program is in Phase 2/3 study 7. MK-3475A to be marketed in the EU as KEYTRUDA SC
MK-8748
Eye Disorders
Ophthalmology V181
Dengue Fever Virus
Vaccines
Phase 3	Phase 2

-- 34 of 34 --